Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Global Cystic Fibrosis Therapeutics Market Growth at CAGR of 31.9%, 2016-2020: Key Vendors are AbbVie, F. Hoffmann-La Roche, Gilead Sciences, Novartis & Vertex Pharmaceuticals - Research and Markets

Research and Markets
Posted on: 07 Nov 16

Research and Markets has announced the addition of the "Global Cystic Fibrosis Therapeutics Market 2016-2020" report to their offering.

The global cystic fibrosis therapeutics market to grow at a CAGR of 31.9% during the period 2016-2020.

Global Cystic Fibrosis Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Cystic fibrosis, also known as mucoviscidosis, is a genetically inherited, chronic disease and is progressive in nature. The onset of cystic fibrosis typically occurs in early childhood or, rarely, at birth. The primary symptoms of cystic fibrosis include breathing difficulties, high salt content in the sweat, and secretion of abnormally viscous mucus. The principal indicators of cystic fibrosis in patients are pancreatic insufficiency, pancreatitis, chronic bronchitis, adolescent diabetes, male sterility, and very rarely liver cirrhosis or intestinal obstruction.

The most usual forms of cystic fibrosis are those with respiratory complications, difficulties related to digestion, and anomalies in height and growth. The mortality and morbidity of a patient are dependent on the degree of bronchopulmonary involvement.

Key vendors

  • AbbVie
  • F. Hoffmann-La Roche
  • Gilead Sciences
  • Novartis
  • Vertex Pharmaceuticals

Other prominent vendors

  • Advanced Inhalation Therapies (AIT)
  • Alaxia SAS
  • Alcresta Therapeutics
  • AlgiPharma
  • Allergan
  • Anthera
  • AstraZeneca
  • Bayer
  • Celtaxsys
  • Chiesi Farmaceutici
  • Corbus Pharmaceuticals
  • Cyclacel Pharmaceuticals
  • Digestive Care
  • Galapagos
  • Grifols
  • Insmed Incorporated
  • Kamada
  • Nivalis Therapeutics
  • Novoteris
  • Parion Sciences
  • Pharmaxis
  • ProQR Therapeutics
  • Protalix Biotherapeutics
  • Proteostasis Therapeutics
  • PTC Therapeutics
  • Pulmatrix
  • Savara
  • SolAeroMed
  • Vectura

Key Topics Covered:

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Market research methodology

Part 04: Introduction

Part 05: Disease overview

Part 06: Pipeline analysis

Part 07: Market landscape

Part 08: Market segmentation by drug class

Part 09: Market segmentation by molecule type

Part 10: Geographical segmentation

Part 11: Key leading countries

Part 12: Market drivers

Part 13: Impact of drivers

Part 14: Market challenges

Part 15: Impact of drivers and challenges

Part 16: Market trends

Co-pay and assistance programs by vendors

Part 17: Vendor landscape

Part 18: Key vendor analysis

Part 19: Appendix

For more information about this report visit

View source version on

Business Wire

Last updated on: 07/11/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.